Literature DB >> 26541540

Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma.

Wilko Weichert1, Claudia Kossakowski2, Alexander Harms2, Peter Schirmacher2, Thomas Muley3, Hendrik Dienemann4, Arne Warth5.   

Abstract

Recent studies in lung adenocarcinoma established a clinically relevant histomorphology-based classification. In contrast, no morphological classifiers have yet been implemented into routine diagnostics for lung squamous cell carcinoma (SQCC). However, morphology-based characteristics putatively impacting on survival have been proposed.We analysed a cohort of 541 SQCC patients with complete clinical follow-up data for morphological characteristics (keratinisation, tumour cell budding, size of tumour cell nests, nuclear size and stromal content). Morphological characteristics were correlated with clinical data and patient outcome.Keratinisation, budding, stromal content and tumour cell nest size, but not nuclear size, were associated with distinct clinicopathological characteristics and survival. SQCC patients with keratinisation, small cell nest size, high stromal content and extensive budding had shorter overall survival. A combined grading scheme composed of the two most reliable validated prognostic markers, i.e. budding and nest size, resulted in an age-, stage- and sex-independent prognosticator for overall survival with a hazard ratio of 1.6 for grade 2 tumours and a hazard ratio of 3.7 for grade 3 tumours when compared with grade 1 neoplasms (p<0.001).Morphological characteristics of SQCC have significant prognostic impact and could constitute the basis for a diagnostically relevant future SQCC grading scheme.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2015        PMID: 26541540     DOI: 10.1183/13993003.00937-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  28 in total

Review 1.  [Grading of lung cancer].

Authors:  R M Bohle; P A Schnabel
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

Review 2.  [The new TNM classification for lung tumors : Changes and the assessment of multiple tumor foci].

Authors:  A Harms; M Kriegsmann; L Fink; F Länger; A Warth
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

3.  FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.

Authors:  Fidelis Andrea Flockerzi; Cristiana Roggia; Frank Langer; Bernd Holleczek; Rainer M Bohle
Journal:  Virchows Arch       Date:  2017-12-21       Impact factor: 4.064

Review 4.  [Morphology of non cutaneous head and neck squamous cell carcinoma].

Authors:  W Weichert; S Ihrler; M Boxberg; A Agaimy; M Mollenhauer; A Hartmann
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

5.  Spread through air spaces (STAS): prognostic impact of a semi-quantitative assessment.

Authors:  Arne Warth
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 6.  [Aerogenic tumor seeding : A new invasive criterion for lung carcinomas].

Authors:  A Warth; L Fink
Journal:  Pathologe       Date:  2018-05       Impact factor: 1.011

Review 7.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

8.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Authors:  Shaohua Lu; Kay See Tan; Kyuichi Kadota; Takashi Eguchi; Sarina Bains; Natasha Rekhtman; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2016-09-28       Impact factor: 15.609

Review 9.  Spread through air spaces (STAS): a comprehensive update.

Authors:  Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 10.  [Grading of head and neck neoplasms].

Authors:  A Agaimy; W Weichert
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.